Effects of a selective 5‐HT 2 agonist, DOI, on 5‐HT neuronal firing in the dorsal raphe nucleus and 5‐HT release and metabolism in the frontal cortex

Systemic administration of the 5‐HT 2 agonist 1‐(2,5‐dimethoxy‐4‐iodophenyl)‐2‐aminopropane (DOI) (50 and 100 μg kg −1 , i.v.) inhibited dorsal raphe neuronal firing. DOI (100 μg kg −1 , i.v.) also produced a decrease in extracellular 5‐hydroxytryptamine (5‐HT) and 5‐hydroxyindoleacetic acid (5‐HIAA...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of pharmacology Vol. 99; no. 2; pp. 221 - 222
Main Authors Wright, Ian K., Garratt, Jeni C., Marsden, C.A.
Format Journal Article
LanguageEnglish
Published 01.02.1990
Online AccessGet full text

Cover

Loading…
More Information
Summary:Systemic administration of the 5‐HT 2 agonist 1‐(2,5‐dimethoxy‐4‐iodophenyl)‐2‐aminopropane (DOI) (50 and 100 μg kg −1 , i.v.) inhibited dorsal raphe neuronal firing. DOI (100 μg kg −1 , i.v.) also produced a decrease in extracellular 5‐hydroxytryptamine (5‐HT) and 5‐hydroxyindoleacetic acid (5‐HIAA) in the frontal cortex measured by microdialysis. However, local administration of DOI into the frontal cortex produced no change in extracellular 5‐HT and 5‐HIAA at any dose given (1, 10 and 100 ng). The results demonstrate that DOI is a potent inhibitor of 5‐HT neuronal firing and terminal release and that the effects on release are not mediated by an action within the terminal region. The site of action and the receptor involved in the inhibition remains to be determined.
ISSN:0007-1188
1476-5381
DOI:10.1111/j.1476-5381.1990.tb14683.x